1Department of Women's and Children's Health, University of Otago, Dunedin, New Zealand.
2Department of Paediatrics, University of Otago, Christchurch, New Zealand.
Diabetes Care. 2023 Mar 1;46(3):628-632. doi: 10.2337/dc22-1971.
To evaluate glycemic outcomes in youth (aged 13-25 years) with type 1 diabetes and high-risk glycemic control (HbA1c ≥8.5% [69 mmol/mol]) on multiple daily injection (MDI) therapy after transitioning to advanced hybrid closed loop (AHCL) therapy.
This prospective, 3-month, single-arm, dual-center study enrolled 20 participants, and all completed the study.
HbA1c decreased from 10.5 ± 2.1% (91.2 ± 22.8 mmol/mol) at baseline to 7.6 ± 1.1% (59.7 ± 11.9 mmol/mol), and time spent in target range 70-180 mg/dL (3.9-10.0 mmol/L) increased from 27.6 ± 13.2% at baseline to 66.5 ± 9.8% after 3 months of AHCL. Two episodes of diabetic ketoacidosis attributed to infusion set failure occurred.
AHCL has the potential to improve suboptimal glycemia in youth with type 1 diabetes previously on MDI therapy.
评估在接受多次每日注射(MDI)治疗后转为先进混合闭环(AHCL)治疗的 13-25 岁、血糖控制高风险(HbA1c≥8.5%[69mmol/mol])的 1 型糖尿病青年患者的血糖控制结果。
这是一项前瞻性、3 个月、单臂、双中心研究,共纳入 20 名参与者,所有人均完成了研究。
HbA1c 从基线时的 10.5±2.1%(91.2±22.8mmol/mol)降至 7.6±1.1%(59.7±11.9mmol/mol),目标范围内时间(70-180mg/dL[3.9-10.0mmol/L])从基线时的 27.6±13.2%增加到 3 个月时的 66.5±9.8%。有两起因输注套件故障导致的糖尿病酮症酸中毒事件。
AHCL 有可能改善之前接受 MDI 治疗的 1 型糖尿病青年患者的血糖控制不佳的情况。